ClinicalTrials.gg
Not yet recruitingNCT06992349Updated May 28, 2025

Bioptron Light Therapy for Dysmenorrhea in Obese Adolesences: RCT

An interventional study of bioptron light therapy in Dysmenorrhea Primary and Obesity and Overweight, sponsored by Alaa Noureldeen Kora. Not yet recruiting at 1 site in Egypt. Open to female participants aged 16 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Alaa Noureldeen Kora · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
16 Years to 18 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 138 studies in Obesity with a site in Egypt — 32 open to participants now, 39 under way, none of them phase 3. Obesity · Egypt.

Planned enrollment
18th of 102
144 · median 60
Started
2025
with 22 others
No phase
90 of 138
21 open now
Primary completion
2025-08
later than 19 of 38 live
Registered
96th of 138
by date

Among the 138 studies in Obesity with a site in Egypt, this one is the 18th largest by planned enrollment of the 102 interventional ones that give a count, is one of 23 that started in 2025, is one of 90 with no phase, reaches primary completion later than 19 of the 38 other live ones, and was the 96th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

32 of the 138 studies in Obesity with a site in Egypt are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 16 Years to 18 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Obesity with a site in Egypt, or all of them as a file.
02

Study summary

Dysmenorrhea is the most common health problem in women in the reproductive age(Bakhsh et al., 2022). The primary dysmenorrhea starts shortly after the menarche the pain lasting 1 to 3 days that start just before or at the onset of menstruation with the absence of other gynecological symptoms (Itani et al., 2022). Primary dysmenorrhea can reduce the quality of life and social activities of women(Esan et al., 2024).

There is a relationship between body mass composition and primary dysmenorrhea and as the value of body mass index and body fat percentages goes on increasing in females, the severity of primary dysmenorrhea also increased (Wu et al., 2022).

BIOPTRON® Light therapy system is a device that contains an optical unit. This unit emits light with an electromagnetic spectrum produced by the sun, but without the ultraviolet rays and it is significant with four main characteristics which are Polarization, Polychromatic, Incoherence and low energy light (Raeissadat et al., 2014).

The Purpose of the Study The aim of the study is to investigate the effect of bioptron© light therapy on primary dysmenorrhoea outcomes as pain and quality of life among obese adolescence.

03

Conditions studied

  • Dysmenorrhea Primary
  • Obesity and Overweight
04

Who can participate

Ages eligible
16 Years to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 144 female adolescences suffering from primary dysmenorrhea pain determined according to the sample size calculation adapted from (Gu et al., 2022).
  • They will be selected from the outpatient's clinic of the faculty of Physical Therapy Sinai University.
  • Their chronological age ranged from 16 to 18 years old.

Exclusion criteria

Exclusion Criteria:

  • Those who were taking anti-psychotic or anti-depressant medications, patients with any skin lesion or infection.
  • Gynecological disorders included cervical cancer, ovarian tumors, endometriosis, uterine fibroids, polycystic ovarian syndrome, and other conditions that can affect menstruation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Group 1: women with BMI more than 30 and receive active bioptron©

    Device: bioptron light therapy

  • Experimental
    Group 2: women with BMI between 18.5 to 25 and receive active bioptron©.

    Device: bioptron light therapy

Interventions

  • Devicebioptron light therapy

    BIOPTRON® Hyperlight is a proprietary, optimized blend of visible and infrared light properties that Bio-stimulate cells and speeding up the healing process of a wide range of medical diseases. Bioptron© light therapy has been utilized as a non-invasive treatment for wound healing, skin ulcers, and various musculoskeletal conditions(Abd Elhamid et al., 2020).

06

What researchers measure

Primary outcomes

  1. number of anatomical pain locations, pain range, number of days of pain during menstruation (and frequency of disabling pain to perform their activities.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)".

Secondary outcomes

  1. Numerical Rating Scale (NRS): is a single-item question that asks the patient to rate the pain on a scale of 0 to 10.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)".

  2. Algometer is an objective measurement of the degree of pressure required to evoke a painful response over selected trigger points.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)".

  3. The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure health-related quality of life.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)".

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Aug 2025, 0 months later.

Of 3,690 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 0 months is below that.

Counting every sponsor, half of 3,853 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
May 28, 2025
StartEst.
Aug 1, 2025
Primary completionEst.
Aug 31, 2025
CompletionEst.
Aug 31, 2025
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06992349
Lead sponsor
Alaa Noureldeen Kora
Responsible party
Alaa Noureldeen Kora (Principal Investigator, Sinai University) — Sponsor-investigator
First posted
May 28, 2025
Start date
Aug 1, 2025 (estimated)
Primary completion
Aug 31, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
May 28, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion